12,372 trials
Attention Deficit-Hyperactivity
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In — 37.2 score on a scale
Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, MDR
Primary: Incidence of Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) Through Follow up Until 26 Weeks After the End of Treatment — 41; 40; 41; 37 Participants
Migraine · Migraine With Aura · Migraine Without Aura
Primary: Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose — 69; 68; 53 Participants
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis) — 1.4; 3.9; 4.1; 5.4 Percentage of Participants — p=0.0012
Cystic Fibrosis
Primary: Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites — 0.00; 3.44; 3.69; 0.00 micrograms per milliliter (mcg/ml)
Hospital-Acquired Bacterial Pneumonia · Ventilator-Associated Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality Through Day 28 in the Modified Intent to Treat (MITT) Population — 11.2; 5.9 Percentage of Participants — p=0.024
Nasopharyngeal Carcinoma
Primary: Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma. — 25; 24.9 Months — p=0.1942
Hypogonadism, Male
Primary: Percentage of Male Hypogonadal Subjects With Average NaF/EDTA Plasma Total Testosterone (T Cavg) Within the Normal Range Using Oral SOV2012-F1. — 166 Participants
Glabellar Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND…
Osteopenia
Primary: Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group. — 2098.7; 1993.3; 2001; 2105.89 mg^2/mm^4 — p=0.7
Thermal Burns
Primary: Primary Endpoint: Number of Participants With Complete Eschar Removal. — 70; 1 Participants — p=<0.0001
Breast Cancer
Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer…
Hereditary Angioedema
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) — 11; 1; 8; 1 Participants
Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases
Primary: Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI) Due to Any Laboratory-Confirmed Influenza Strains — 118; 130 Number of cases
Urinary Tract Infections
Primary: Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S…